These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16188442)

  • 21. Endocrine therapy for advanced/metastatic breast cancer.
    Schiavon G; Smith IE
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
    Burdette-Radoux S; Muss HB
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of endocrine treatments for breast cancer on health-related quality of life.
    Buijs C; de Vries EG; Mourits MJ; Willemse PH
    Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
    Trunet P; Marty M
    Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors for the treatment and prevention of breast cancer.
    Kalidas M; Brown P
    Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in the treatment of postmenopausal breast cancer.
    Howell A
    Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
    Iwase H; Yamamoto Y
    Int J Clin Oncol; 2015 Apr; 20(2):253-61. PubMed ID: 25673474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Drugs; 2007; 67(16):2335-53. PubMed ID: 17983255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.
    Kudachadkar R; O'Regan RM
    CA Cancer J Clin; 2005; 55(3):145-63. PubMed ID: 15890638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renaissance of endocrine therapy in breast cancer.
    Williams N; Harris LN
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):41-7. PubMed ID: 24346127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.